Can we expect Darzalex to receive expanded reimb this year?
By Eo, Yun-Ho | translator Kim, Jung-Ju
24.02.17 05:50:45
가나다라
0
The first-and second-line combination therapies expected to be considered for the Drug Reimbursement Committee
After receiving the expanded indication, the discussion for listing has been delayed
▲Janssen Korea’s Darzalex (daratumumab).
A multiple myeloma drug, ‘Darzalex,’ garners attention as to whether it could receive expanded use this year.Janssen Korea’s Darzalex (daratumumab) is under discussion for expanding reimbursement into multiple indications.
It is categorized into two types of therapies. The first is the DVTd (daratumumab, bortezomib, thalidomide, and dexamethasone) combination therapy, which cleared the Cancer Drug Review Committee of the Health Insurance Review and Assessment Service (HIRA) last May as the first-line treatment of multiple myeloma.
Another is a combination therapy, including DRd (daratumumab, lenalidomide, and dexamethasone), DVd (daratumumab, bortezomib, and dexameth
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)